PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.05%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-91.56%
Negative gross profit growth while FSLR is at 21.18%. Joel Greenblatt would examine cost competitiveness or demand decline.
-117.68%
Negative EBIT growth while FSLR is at 61.98%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
52.17%
Operating income growth at 75-90% of FSLR's 61.98%. Bill Ackman would demand a plan to enhance operating leverage.
-19.73%
Negative net income growth while FSLR stands at 57.35%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
5.26%
EPS growth under 50% of FSLR's 56.87%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
-2636.84%
Negative diluted EPS growth while FSLR is at 57.23%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.11%
Share count expansion well above FSLR's 0.01%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.11%
Diluted share count expanding well above FSLR's 0.21%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-16.64%
Negative OCF growth while FSLR is at 284.47%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
37.43%
FCF growth 50-75% of FSLR's 74.43%. Martin Whitman would see if structural disadvantages exist in generating free cash.
-54.63%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-19.07%
Negative 5Y CAGR while FSLR stands at 16.21%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
52.14%
Positive 3Y CAGR while FSLR is negative. John Neff might view this as a sharp short-term edge or successful pivot strategy.
-148.30%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
89.98%
5Y OCF/share CAGR at 50-75% of FSLR's 172.07%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
55.23%
Positive 3Y OCF/share CAGR while FSLR is negative. John Neff might see a big short-term edge in operational efficiency.
-123.86%
Negative 10Y net income/share CAGR while FSLR is at 27.16%. Joel Greenblatt sees a major red flag in long-term profit erosion.
66.53%
Below 50% of FSLR's 355.93%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-181.28%
Negative 3Y CAGR while FSLR is 71.71%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-72.89%
Negative equity/share CAGR over 10 years while FSLR stands at 31.78%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
707.78%
5Y equity/share CAGR above 1.5x FSLR's 19.56%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
4083.36%
3Y equity/share CAGR above 1.5x FSLR's 15.85%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.69%
Firm’s AR is declining while FSLR shows 17.76%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-23.48%
Inventory is declining while FSLR stands at 41.45%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-8.03%
Negative asset growth while FSLR invests at 6.51%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-11.43%
We have a declining book value while FSLR shows 4.34%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-9.91%
We’re deleveraging while FSLR stands at 24.21%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-16.93%
Our R&D shrinks while FSLR invests at 12.10%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-79.07%
We cut SG&A while FSLR invests at 8.30%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.